Regulatory · Sport
Peptides on the WADA Prohibited List, 2026 and 2027
Where each of the 299 compounds in our encyclopedia stands under the World Anti-Doping Agency's Prohibited List: named, caught by the S0 catch-all, unsettled, or not on the List. Under the 2027 List, which takes effect on January 1, 2027: 73 named on the List, 1 prohibited in competition only, 114 caught by S0 without being named, 50 unsettled, 61 not on the List.
Lists read September 27, 2026 · Rendered from our dataset on 2026-10-01 · By the Grey Peptides Editorial Board
Which List applies
The 2026 List has been in force since January 1, 2026, and is the one that applies today. WADA approved the 2027 List on September 10, 2026, published it on September 21, and it takes effect on January 1, 2027. What matters for an athlete is the List in force on the date of the sample, which is why this page shows both.
Four ways a peptide can stand
Named. A section of the List names the substance or a class that includes it. Most peptides that are named appear under S2, the section for peptide hormones, growth factors and related substances, and are prohibited at all times.
Caught by S0. S0 prohibits any pharmacological substance that no other section addresses and that has no current approval by any governmental regulatory health authority for human therapeutic use. The List's own examples include drugs under pre-clinical or clinical development or discontinued, and substances approved only for veterinary use. S0's text now lists “peptides” among its examples of non-approved substances. This is why most research peptides are prohibited although almost none is named: S0 reaches them because nobody has approved them.
Unsettled. Not named, and S0's test turns on a fact we have not settled: an approval somewhere outside the US that we have not verified, or an approval for diagnostic rather than therapeutic use. We say so rather than guess, and each row gives the reason.
Not on the List. Neither named nor caught by S0. Usually that is because the compound is approved somewhere for human therapeutic use and no section names it.
Specified or not
The List designates every prohibited substance as Specified except those in the sections it names as exceptions, and the distinction affects how a case is sanctioned under the World Anti-Doping Code. The List is explicit that a Specified substance should not in any way be considered less important or less dangerous than any other. The table gives the designation for every prohibited compound.
What changed for 2027
S0's text now lists “peptides” among its examples of non-approved substances. Compound by compound, against our records:
- Dermorphin: “Not on the 2026 List” became “Unsettled (S0 may apply)” for 2027. WADA monitored dermorphin as a non-prohibited substance in 2026 and dropped it from the 2027 Monitoring Program without adding it to the List; on its face S0 would cover it.
Named on the List (73)
The List names the substance, or a class that plainly includes it, in a section. Where it is named, the List's own words are quoted.
Show all 73
| Compound | 2027 List | Specified? | Notes |
|---|---|---|---|
| ACE-031 | Prohibited at all times (S4.3) | Non-Specified | The List: “Decoy activin receptors (e.g. ACE-031)” |
| Anamorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “anamorelin” |
| AOD-9604 | Prohibited at all times (S2.2.3) | Non-Specified | The List: “AOD-9604” Named as a growth hormone fragment, alongside hGH 176-191. |
| Apitegromab | Prohibited at all times (S4.3) | Non-Specified | The List: “apitegromab” |
| ARA-290 | Prohibited at all times (S2.1.5) | Non-Specified | ARA-290 (cibinetide) is an EPO-derived peptide that activates the innate repair receptor, the class S2.1.5 names. |
| Bimagrumab | Prohibited at all times (S4.3) | Non-Specified | The List: “bimagrumab” |
| BPC-157 | Prohibited at all times (S0) | Specified | The List: “BPC-157” It is the first substance S0 names, on page 4 of both Lists. |
| Buserelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “buserelin” |
| Capromorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “capromorelin” |
| CJC-1295 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “CJC-1295” Named alongside CJC-1293 as a GHRH analogue. |
| Corticorelin | Prohibited at all times (S2.2.2) | Non-Specified | The List: “corticorelin” |
| Desmopressin | Prohibited at all times (S5) | Specified | The List: “Desmopressin” |
| Eftansomatropin alfa | Prohibited at all times (S2.2.3) | Non-Specified | A long-acting growth hormone; approval in South Korea does not lift an S2 listing. |
| Erythropoietin (EPO) | Prohibited at all times (S2.1.1) | Non-Specified | The List: “erythropoietins (EPO)” |
| Examorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “examorelin (hexarelin)” The same molecule as hexarelin. |
| Felypressin | Prohibited at all times (S5) | Specified | The List: “Local administration of felypressin in dental anaesthesia” The List mentions felypressin only to exempt local dental use; given any other way it is an S5 masking agent. |
| Follistatin-315 | Prohibited at all times (S4.3) | Non-Specified | The List: “e.g. follistatin, myostatin propeptide” Named as an example of the myostatin-binding proteins. |
| Follistatin-344 | Prohibited at all times (S4.3) | Non-Specified | The List: “e.g. follistatin, myostatin propeptide” Named as an example of the myostatin-binding proteins. |
| Garetosmab | Prohibited at all times (S4.3) | Non-Specified | An anti-activin A antibody. |
| Ghrelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “lenomorelin (ghrelin)” |
| GHRP-2 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “GHRP-2 (pralmorelin)” |
| GHRP-6 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “GHRP-6” |
| Gonadorelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “GnRH, gonadorelin” |
| Goserelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “goserelin” |
| HCG | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “chorionic gonadotrophin (CG)” |
| Hexarelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “examorelin (hexarelin)” |
| HGH Fragment 176-191 | Prohibited at all times (S2.2.3) | Non-Specified | The List: “hGH 176-191” |
| Histrelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “histrelin” |
| IGF-1 | Prohibited at all times (S2.3) | Non-Specified | The List: “Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues” |
| IGF-1 DES(1-3) | Prohibited at all times (S2.3) | Non-Specified | A truncated IGF-1 that also occurs naturally in small amounts. |
| IGF-1 LR3 | Prohibited at all times (S2.3) | Non-Specified | — |
| Insulin aspart | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin degludec | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin degludec / liraglutide (IDegLira) | Prohibited at all times (S4.4.2) | Non-Specified | Contains insulin degludec, prohibited as a class under S4.4.2; its liraglutide is not listed. |
| Insulin detemir | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin efsitora alfa | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin glargine | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin glargine / lixisenatide (iGlarLixi) | Prohibited at all times (S4.4.2) | Non-Specified | Contains insulin glargine, prohibited as a class under S4.4.2; its lixisenatide is not listed. |
| Insulin glulisine | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin icodec | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Insulin lispro | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Ipamorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “ipamorelin” |
| Kisspeptin-10 | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “kisspeptin and its agonist analogues” |
| Kisspeptin-54 | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “kisspeptin and its agonist analogues” |
| Leuprolide | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “leuprorelin” |
| Lixivaptan | Prohibited at all times (S5) | Specified | A vaptan: S5 names the class and three of its members. |
| Lonapegsomatropin | Prohibited at all times (S2.2.3) | Non-Specified | The List: “lonapegsomatropin” A long-acting growth hormone analogue. |
| Lutropin alfa | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “luteinizing hormone (LH)” Lutropin alfa is recombinant human LH. |
| Macimorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “macimorelin” |
| Mecasermin | Prohibited at all times (S2.3) | Non-Specified | The List: “IGF-1, mecasermin” |
| Mecasermin rinfabate | Prohibited at all times (S2.3) | Non-Specified | A complex of mecasermin, which the List names, with its binding protein IGFBP-3. |
| Menotropin | Prohibited in males, at all times (S2.2.1) | Non-Specified | Human menopausal gonadotrophin contains LH activity, and LH is named; FDA approval does not lift an S2 listing. |
| MGF | Prohibited at all times (S2.3) | Non-Specified | The List: “Mechano growth factors (MGFs)” |
| MK-677 | Prohibited at all times (S2.2.4) | Non-Specified | The List: “ibutamoren (MK-677)” |
| Mod GRF 1-29 | Prohibited at all times (S2.2.4) | Non-Specified | A GHRH analogue sold as “CJC-1295 without DAC”; the List names CJC-1293 and CJC-1295 and covers every GHRH analogue. |
| MOTS-c | Prohibited at all times (S4.4.1) | Non-Specified | The List: “mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)” Listed as an AMPK activator alongside AICAR, not under S2 as is often claimed. |
| Nafarelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “nafarelin” |
| NPH insulin (isophane) | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| PEG-MGF | Prohibited at all times (S2.3) | Non-Specified | PEG-MGF itself is not named: it is a pegylated mechano growth factor, caught by S2's rule covering substances of similar chemical structure or biological effect. |
| Pralmorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “GHRP-2 (pralmorelin)” Being approved in Japan does not lift this: S2 naming is independent of approval status. |
| Regular human insulin | Prohibited at all times (S4.4.2) | Non-Specified | Insulins are prohibited as a class; athletes with diabetes use them under a Therapeutic Use Exemption. |
| Relamorelin | Prohibited at all times (S2.2.4) | Non-Specified | A ghrelin-receptor agonist, the receptor the named secretagogues act on. |
| Sermorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “sermorelin” |
| Somapacitan | Prohibited at all times (S2.2.3) | Non-Specified | The List: “somapacitan” A long-acting growth hormone analogue. |
| Somatrogon | Prohibited at all times (S2.2.3) | Non-Specified | The List: “somatrogon” A long-acting growth hormone analogue. |
| Somatropin (HGH) | Prohibited at all times (S2.2.3) | Non-Specified | The List: “Growth hormone (GH), its analogues and fragments” Approval does not exempt a substance from the List. |
| Tabimorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “tabimorelin” |
| Taldefgrobep alfa | Prohibited at all times (S4.3) | Non-Specified | An anti-myostatin adnectin: S4.3 prohibits myostatin inhibitors. |
| TB-500 | Prohibited at all times (S2.3) | Non-Specified | The List: “Thymosin-ß4 and its derivatives e.g. TB-500” |
| Tesamorelin | Prohibited at all times (S2.2.4) | Non-Specified | The List: “tesamorelin” FDA-approved and WADA-prohibited at the same time: the two regimes are unrelated. |
| Thymosin β4 | Prohibited at all times (S2.3) | Non-Specified | The List: “Thymosin-ß4 and its derivatives” |
| Trevogrumab | Prohibited at all times (S4.3) | Non-Specified | An anti-myostatin antibody. |
| Triptorelin | Prohibited in males, at all times (S2.2.1) | Non-Specified | The List: “triptorelin” |
Prohibited in competition only (1)
Named in a section that applies only in competition.
| Compound | 2027 List | Specified? | Notes |
|---|---|---|---|
| Tesofensine | Prohibited in competition (S6.B) | Specified | The List: “Tesofensine” |
Not named, but caught by S0 (114)
Not named anywhere, and approved nowhere for human therapeutic use, so S0, the catch-all, applies.
Show all 114
| Compound | 2027 List | Specified? | Notes |
|---|---|---|---|
| 5-Amino-1MQ | Prohibited (S0 catch-all) | Specified | — |
| Adamax | Prohibited (S0 catch-all) | Specified | — |
| Adipotide | Prohibited (S0 catch-all) | Specified | — |
| Adrenomedullin | Prohibited (S0 catch-all) | Specified | — |
| AHK-Cu | Prohibited (S0 catch-all) | Specified | — |
| Albiglutide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Alpha-MSH | Prohibited (S0 catch-all) | Specified | — |
| Amycretin | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Amylin | Prohibited (S0 catch-all) | Specified | — |
| Apelin | Prohibited (S0 catch-all) | Specified | — |
| Apraglutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| AZD6234 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Beta-Endorphin | Prohibited (S0 catch-all) | Specified | — |
| Bradykinin | Prohibited (S0 catch-all) | Specified | — |
| BRN2 (POU3F2) Research Peptide | Prohibited (S0 catch-all) | Specified | — |
| Bronchogen | Prohibited (S0 catch-all) | Specified | — |
| Cagrilintide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| CagriSema | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Cardiogen | Prohibited (S0 catch-all) | Specified | — |
| Cartalax | Prohibited (S0 catch-all) | Specified | — |
| Cathelicidin | Prohibited (S0 catch-all) | Specified | — |
| Cecropin | Prohibited (S0 catch-all) | Specified | — |
| Cerluten | Prohibited (S0 catch-all) | Specified | — |
| CGRP | Prohibited (S0 catch-all) | Specified | — |
| Chonluten | Prohibited (S0 catch-all) | Specified | — |
| CNP | Prohibited (S0 catch-all) | Specified | — |
| Cortagen | Prohibited (S0 catch-all) | Specified | — |
| Cotadutide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Danuglipron | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Davunetide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Dermcidin | Prohibited (S0 catch-all) | Specified | — |
| Dihexa | Prohibited (S0 catch-all) | Specified | — |
| DSIP | Prohibited (S0 catch-all) | Specified | — |
| Dynorphin | Prohibited (S0 catch-all) | Specified | — |
| ECC5004 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Efpeglenatide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Elsiglutide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Endoluten | Prohibited (S0 catch-all) | Specified | — |
| Endothelin-1 | Prohibited (S0 catch-all) | Specified | — |
| Enkephalin | Prohibited (S0 catch-all) | Specified | — |
| Epithalon | Prohibited (S0 catch-all) | Specified | — |
| FGL Peptide | Prohibited (S0 catch-all) | Specified | — |
| FK-13 | Prohibited (S0 catch-all) | Specified | — |
| FOXO4-DRI | Prohibited (S0 catch-all) | Specified | — |
| Galanin | Prohibited (S0 catch-all) | Specified | — |
| GDF11 | Prohibited (S0 catch-all) | Specified | — |
| GDF15 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| GHK-Cu | Prohibited (S0 catch-all) | Specified | — |
| GIP | Prohibited (S0 catch-all) | Specified | — |
| Glepaglutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| GLP-2 | Prohibited (S0 catch-all) | Specified | — |
| GMA106 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| hBD-1 | Prohibited (S0 catch-all) | Specified | — |
| hBD-2 | Prohibited (S0 catch-all) | Specified | — |
| hBD-3 | Prohibited (S0 catch-all) | Specified | — |
| HD5 | Prohibited (S0 catch-all) | Specified | — |
| HD6 | Prohibited (S0 catch-all) | Specified | — |
| Histatin | Prohibited (S0 catch-all) | Specified | — |
| HM15136 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| HM15275 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| HNP-1 | Prohibited (S0 catch-all) | Specified | — |
| HNP-2 | Prohibited (S0 catch-all) | Specified | — |
| HNP-3 | Prohibited (S0 catch-all) | Specified | — |
| HRS-9531 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Humanin | Prohibited (S0 catch-all) | Specified | — |
| Klotho Peptide | Prohibited (S0 catch-all) | Specified | — |
| KN056 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| KPV | Prohibited (S0 catch-all) | Specified | — |
| KR-12 | Prohibited (S0 catch-all) | Specified | — |
| Lactoferricin | Prohibited (S0 catch-all) | Specified | — |
| Langlenatide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Larazotide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Livagen | Prohibited (S0 catch-all) | Specified | — |
| LL-37 | Prohibited (S0 catch-all) | Specified | — |
| Magainin | Prohibited (S0 catch-all) | Specified | — |
| Maridebart cafraglutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Melanotan II | Prohibited (S0 catch-all) | Specified | — |
| Melittin | Prohibited (S0 catch-all) | Specified | — |
| NA-Selank Amidate | Prohibited (S0 catch-all) | Specified | — |
| Neuropeptide Y | Prohibited (S0 catch-all) | Specified | — |
| Neurotensin | Prohibited (S0 catch-all) | Specified | — |
| NPAS3 Research Peptide | Prohibited (S0 catch-all) | Specified | — |
| Omiganan | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Orexin-A | Prohibited (S0 catch-all) | Specified | — |
| Orexin-B | Prohibited (S0 catch-all) | Specified | — |
| Ovagen | Prohibited (S0 catch-all) | Specified | — |
| P21 | Prohibited (S0 catch-all) | Specified | — |
| PB-718 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| PE-22-28 | Prohibited (S0 catch-all) | Specified | — |
| Pemvidutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Peptide YY | Prohibited (S0 catch-all) | Specified | — |
| Petrelintide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Pexiganan | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Pinealon | Prohibited (S0 catch-all) | Specified | — |
| PNC-27 | Prohibited (S0 catch-all) | Specified | — |
| Prostamax | Prohibited (S0 catch-all) | Specified | — |
| Protirelin | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Retatrutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| SHLP1 | Prohibited (S0 catch-all) | Specified | — |
| SHLP2 | Prohibited (S0 catch-all) | Specified | — |
| SHLP3 | Prohibited (S0 catch-all) | Specified | — |
| SHLP4 | Prohibited (S0 catch-all) | Specified | — |
| SHLP5 | Prohibited (S0 catch-all) | Specified | — |
| SHLP6 | Prohibited (S0 catch-all) | Specified | — |
| Substance P | Prohibited (S0 catch-all) | Specified | — |
| Survodutide | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
| Taspoglutide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Testagen | Prohibited (S0 catch-all) | Specified | — |
| Thymulin | Prohibited (S0 catch-all) | Specified | — |
| Ularitide | Prohibited (S0 catch-all) | Specified | A discontinued drug: S0's own examples include discontinued drugs. |
| Ventfort | Prohibited (S0 catch-all) | Specified | — |
| Vesugen | Prohibited (S0 catch-all) | Specified | — |
| Visoluten | Prohibited (S0 catch-all) | Specified | — |
| VK2735 | Prohibited (S0 catch-all) | Specified | An investigational drug: S0's own examples include drugs under clinical development. |
Unsettled (50)
Not named, and whether S0 applies turns on a fact this site has not settled, such as an approval outside the US or an approval for diagnostic use only. Each row says which.
Show all 50
| Compound | 2027 List | Specified? | Notes |
|---|---|---|---|
| Abarelix | Unsettled (S0 may apply) | Specified | Withdrawn from the US market in 2005; our entry notes it is still sold in some markets, which we have not verified. A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. |
| Acetyl Hexapeptide-30 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Hexapeptide-37 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Octapeptide-3 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Tetrapeptide-2 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Acetyl Tetrapeptide-5 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| ANP | Unsettled (S0 may apply) | Specified | The same molecule as carperitide, which is approved in Japan (Hanp). |
| Argireline | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Atosiban | Unsettled (S0 may apply) | Specified | — |
| Beinaglutide | Unsettled (S0 may apply) | Specified | — |
| Biotinoyl Tripeptide-1 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Carbetocin | Unsettled (S0 may apply) | Specified | — |
| Carperitide | Unsettled (S0 may apply) | Specified | — |
| Cerebrolysin | Unsettled (S0 may apply) | Specified | — |
| Cholecystokinin | Unsettled (S0 may apply) | Specified | Its octapeptide form, sincalide, is FDA-approved as a diagnostic agent; S0 speaks of approval for therapeutic use. |
| Corifollitropin alfa | Unsettled (S0 may apply) | Specified | Follicle-stimulating hormone is not named, and S2.2.1's examples (CG, LH, GnRH agonists, kisspeptin) are testosterone-stimulating hormones, which FSH is not. |
| Cortexin | Unsettled (S0 may apply) | Specified | — |
| Decorinyl | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Dermorphin | Unsettled (S0 may apply) | Specified | WADA monitored dermorphin as a non-prohibited substance in 2026 and dropped it from the 2027 Monitoring Program without adding it to the List; on its face S0 would cover it. 2026: Not on the 2026 List |
| Ecnoglutide | Unsettled (S0 may apply) | Specified | — |
| Follitropin delta | Unsettled (S0 may apply) | Specified | Follicle-stimulating hormone is not named, and S2.2.1's examples (CG, LH, GnRH agonists, kisspeptin) are testosterone-stimulating hormones, which FSH is not. |
| Glutathione | Unsettled (S0 may apply) | Specified | Sold as a supplement and compounded for injection, never approved as a drug; how S0 treats it has not been decided. Separately, any infusion or injection of more than 100 mL per 12 hours is a prohibited method (M2.2) unless received in hospital treatment, surgery or clinical investigations. |
| Leuphasyl | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Matrixyl | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Mazdutide | Unsettled (S0 may apply) | Specified | — |
| Melatonin | Unsettled (S0 may apply) | Specified | Also sold as a dietary supplement in the US. |
| NAD+ | Unsettled (S0 may apply) | Specified | Not a peptide. Sold as a supplement and compounded for injection, never approved as a drug; how S0 treats it has not been decided. Separately, any infusion or injection of more than 100 mL per 12 hours is a prohibited method (M2.2) unless received in hospital treatment, surgery or clinical investigations. |
| Nesiritide | Unsettled (S0 may apply) | Specified | FDA-approved as Natrecor (NDA 020920, August 10, 2001) and now discontinued in the US; whether an approval is current anywhere is not verified here. |
| Noopept | Unsettled (S0 may apply) | Specified | — |
| Pal-GHK | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Hexapeptide-12 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Pentapeptide-4 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Tetrapeptide-7 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Tripeptide-38 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Palmitoyl Tripeptide-5 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Pegvisomant | Unsettled (S2.2.3 may apply) | Non-Specified | A modified growth hormone that blocks the GH receptor. S2.2.3 covers growth hormone analogues and S2 covers substances of similar chemical structure; the List does not say whether that reaches an antagonist. |
| Pentapeptide-3 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Rigin | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Selank | Unsettled (S0 may apply) | Specified | — |
| Semax | Unsettled (S0 may apply) | Specified | — |
| SNAP-8 | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Syn-Ake | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Terlipressin | Unsettled (S5 may apply) | Specified | Not named. Terlipressin is a prodrug of lysine-vasopressin; S5 names the analogue desmopressin and covers substances with a similar biological effect, without saying whether that reaches terlipressin. |
| Thymalin | Unsettled (S0 may apply) | Specified | — |
| Thymogen | Unsettled (S0 may apply) | Specified | — |
| Thymopentin | Unsettled (S0 may apply) | Specified | — |
| Thymosin α1 | Unsettled (S0 may apply) | Specified | — |
| Tripeptide-10 Citrulline | Unsettled (S0 may apply) | Specified | Sold as a cosmetic ingredient, not a drug. S0 covers pharmacological substances without a drug approval; whether it reaches a topical cosmetic ingredient has not been decided. |
| Vasopressin | Unsettled (S5 may apply) | Specified | Not named. S5 names desmopressin, a vasopressin analogue, and covers substances with a similar biological effect; the List does not say whether vasopressin itself is one. |
| VIP | Unsettled (S0 may apply) | Specified | Our entry records an injectable VIP product approved in some EU countries; we have not verified it. |
Not on the List (61)
Neither named nor caught by S0, usually because the compound is approved somewhere for human therapeutic use and no section names it.
Show all 61
| Compound | 2027 List | Specified? | Notes |
|---|---|---|---|
| Afamelanotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Alprostadil | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Angiotensin II | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Bacitracin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Bioactive Food Peptides | Not on the 2027 List | — | A food or supplement ingredient, not a drug; S0 is written for pharmacological substances. Supplements carry a separate risk: contamination with prohibited substances. 2026: Not on the 2026 List |
| Bivalirudin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| BNP | Not on the 2027 List | — | Measured in blood tests rather than given as a medicine; as a drug it exists only as nesiritide, whose WADA position is set out in that entry. 2026: Not on the 2026 List |
| Botulinum Toxin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Calcitonin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Carnosine | Not on the 2027 List | — | A food or supplement ingredient, not a drug; S0 is written for pharmacological substances. Supplements carry a separate risk: contamination with prohibited substances. 2026: Not on the 2026 List |
| Cetrorelix | Not on the 2027 List | — | A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. 2026: Not on the 2026 List |
| Colistin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Collagen Peptides | Not on the 2027 List | — | A food or supplement ingredient, not a drug; S0 is written for pharmacological substances. Supplements carry a separate risk: contamination with prohibited substances. 2026: Not on the 2026 List |
| Colostrinin | Not on the 2027 List | — | A food or supplement ingredient, not a drug; S0 is written for pharmacological substances. Supplements carry a separate risk: contamination with prohibited substances. 2026: Not on the 2026 List |
| Daptomycin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Degarelix | Not on the 2027 List | — | A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. 2026: Not on the 2026 List |
| Dulaglutide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Elagolix | Not on the 2027 List | — | A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. 2026: Not on the 2026 List |
| Enlicitide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Eptifibatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Exenatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Follitropin alfa | Not on the 2027 List | — | Follicle-stimulating hormone is not named, and S2.2.1's examples (CG, LH, GnRH agonists, kisspeptin) are testosterone-stimulating hormones, which FSH is not. 2026: Not on the 2026 List |
| Follitropin beta | Not on the 2027 List | — | Follicle-stimulating hormone is not named, and S2.2.1's examples (CG, LH, GnRH agonists, kisspeptin) are testosterone-stimulating hormones, which FSH is not. 2026: Not on the 2026 List |
| Ganirelix | Not on the 2027 List | — | A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. 2026: Not on the 2026 List |
| Glatiramer Acetate | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Glucagon | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Gramicidin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Hyaluronic Acid | Not on the 2027 List | — | Not a peptide. 2026: Not on the 2026 List |
| Icatibant | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Icotrokinra | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Lanreotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Linaclotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Liraglutide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Lixisenatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Lutetium-177 DOTATATE | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Navepegritide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Nisin | Not on the 2027 List | — | A food preservative (E 234; GRAS in the US), not a drug. 2026: Not on the 2026 List |
| Octreotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Orforglipron | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Oxytocin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Pasireotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Plecanatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Polymyxin B | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Pramlintide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| PT-141 | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Relugolix | Not on the 2027 List | — | A GnRH antagonist: S2.2.1 covers GnRH and its agonist analogues, not antagonists. 2026: Not on the 2026 List |
| Romiplostim | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Rusfertide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Secretin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Semaglutide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Setmelanotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Somatostatin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| SS-31 (Elamipretide) | Not on the 2027 List | — | S0 does not apply: FDA approved elamipretide (Forzinity) in September 2025, and no section of either List names it or a class it belongs to. This row showed S0? until September 27, 2026. 2026: Not on the 2026 List |
| Teduglutide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Teriparatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Tirzepatide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Urofollitropin | Not on the 2027 List | — | Follicle-stimulating hormone is not named, and S2.2.1's examples (CG, LH, GnRH agonists, kisspeptin) are testosterone-stimulating hormones, which FSH is not. 2026: Not on the 2026 List |
| Vancomycin | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Vosoritide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Ziconotide | Not on the 2027 List | — | 2026: Not on the 2026 List |
| Zilucoplan | Not on the 2027 List | — | 2026: Not on the 2026 List |
Monitored, not prohibited
WADA's Monitoring Program tracks substances that are not prohibited, to detect patterns of misuse. For 2027 it includes 9 compounds in our encyclopedia: Buserelin, Gonadorelin, Goserelin, Histrelin, Leuprolide, Nafarelin, Semaglutide, Tirzepatide, Triptorelin. Being monitored is not being prohibited, but it is WADA saying it is watching.
What an athlete should check
- The List in force on the day. A compound can change status between Lists, as dermorphin does for 2027.
- Not named does not mean permitted. S0 catches unapproved substances whether or not anyone has named them, and the 2027 List adds peptides to its examples.
- A prescription is not an exemption. Where a prohibited substance is medically needed, the route is a Therapeutic Use Exemption, which the List itself refers to.
- A label bought outside the regulated supply is not evidence of what is inside. In one study, semaglutide bought online without a prescription contained 28.6% to 38.7% more than its label stated. Our semaglutide entry covers the findings.
- This page is not a ruling. It reports what the List says and how we read it. An athlete's own anti-doping organisation gives the answer that counts.
Sources
- World Anti-Doping Agency. Prohibited List 2027, approved September 10, 2026, published September 21, 2026, in force January 1, 2027; read September 27, 2026. WADA
- World Anti-Doping Agency. Prohibited List 2027: Summary of Major Modifications and Explanatory Notes. WADA
- World Anti-Doping Agency. 2027 Monitoring Program. WADA
- World Anti-Doping Agency. Prohibited List 2026, in force January 1, 2026; read September 27, 2026. WADA
- Ashraf AR et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription. J Med Internet Res 2024;26:e65440. PMID 39509151. PubMed
- Grey Peptides dataset: each entry's WADA record for both years, with its section, the List's wording where named, and the date reviewed. Dataset · Regulatory tracker · Our report on the 2027 List
This page reports the Prohibited List and our reading of it. It is not legal advice or an anti-doping ruling.